Trastuzumab News and Research

RSS

New type of drug shrinks primary breast cancer tumours significantly in just six weeks

A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) (Thursday 17 April).

17 Apr 2008

Discovery of link between protein, prognosis in breast cancer

Oregon Health & Science University Cancer Institute researchers have found that a tumor protein present in an aggressive form of breast cancer is related to a poor prognosis.

13 Apr 2008

Biomarkers allow doctors to match therapy to patient

Genetic variations ensure that no two people are exactly alike, nor are their cancers.

13 Apr 2008

Benefits of some cancer drugs exaggerated because trials were stopped early

Italian scientists say the benefits of some cancer drugs may be exaggerated as a rising number of trials are stopped early.

9 Apr 2008

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

11 Mar 2008

Cardiac effects associated with breast cancer treatment appear lower

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.

10 Mar 2008

New global study of targeted therapies for breast cancer

Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research.

1 Mar 2008

Breast cancer subtypes linked to survival from secondary brain tumors

Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases.

28 Feb 2008

New method for detecting HER2 breast cancer

Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well.

21 Feb 2008

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

17 Dec 2007

New insight into Herceptin resistance in breast cancer

A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell , identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients.

16 Oct 2007

Report on access to cancer drugs across Europe flawed

A leading epidemiologist has attacked Swedish research that looked at inequalities in patients' access to cancer drugs across Europe and the world.

30 Aug 2007

Latest drugs improve survival for metastatic breast cancer

Newer drug therapies available since the 1990s, in particular aromatase inhibitors, improve the survival of women with metastatic breast cancer in the general population, according to a new study.

23 Jul 2007

Trastuzumab and chemo improves survival in women with operable HER-2 positive breast cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

9 Jul 2007

Novel method of drug delivery to inhibit the growth of prostate cancer cells

Prostate cancer is the second leading cause of cancer-related death for men in the U.S. Present treatments for metastatic prostate cancer (cancer cells that spread to other parts of the body) include hormonal therapy, chemotherapy and radiotherapy, which frequently have serious side effects.

23 Jun 2007

Newer breast cancer drug may protect heart

By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

16 Jun 2007

Herceptin does not increase heart failure in patients long-term

Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

5 Jun 2007

Benefits of Herceptin are lasting

An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.

5 Jun 2007

Combination treatment cures mice of a very aggressive human breast tumor

A combination of three different drugs that block the HER-2 receptor, a critical cellular growth signal for some breast cancers, eradicated aggressive breast tumors in mice and could point the way toward developing better treatments inpatients, said researchers from the Breast Center at Baylor College of Medicine in a report that appears today in the Journal of the National Cancer Institute.

2 May 2007

New role for sugars on proteins

In a ground-breaking study published in the top journal, Cell, Dr. James Dennis, senior investigator at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, has discovered a new role for sugars on proteins.

7 Apr 2007